Gonadotropin-releasing hormone 1 (GNRH1), also known as luteinizing hormone-releasing hormone (LHRH), is a decapeptide produced in the hypothalamus. It plays a pivotal role in regulating reproductive physiology by stimulating the secretion of gonadotropins (LH and FSH) from the pituitary gland, which in turn control steroidogenesis and gametogenesis in the gonads. GNRH1 antibodies are immunodetection tools designed to target and bind specific epitopes of the GNRH1 peptide or its precursor proteins. These antibodies are widely used in research to study the expression, localization, and regulatory mechanisms of GNRH1 in hypothalamic neurons, as well as its involvement in reproductive disorders such as hypogonadism, infertility, and hormone-dependent cancers. In clinical diagnostics, they aid in assessing hypothalamic-pituitary-gonadal axis dysfunction. Additionally, GNRH1 antibodies have therapeutic potential, including the development of immunocontraceptives or treatments for conditions like prostate cancer, where GNRH1 signaling suppression is beneficial. Validation of these antibodies requires careful consideration of specificity due to structural similarities with related peptides across species. Their applications span immunohistochemistry, ELISA, and Western blot, contributing to both basic endocrine research and translational medicine.